Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2003

Open Access 01-12-2003 | Research

Effects of STI571 (gleevec) on pancreatic cancer cell growth

Authors: Junsheng Li, Jörg Kleeff, Junchao Guo, Lars Fischer, Nathalia Giese, Markus W Büchler, Helmut Friess

Published in: Molecular Cancer | Issue 1/2003

Login to get access

Abstract

Background

Pancreatic cancer is an aggressive malignancy characterized by low responsiveness to chemotherapy and radiotherapy. This resistance is partly due to the overexpression of several tyrosine kinase receptors and their ligands. STI571 has specific activity in inhibiting c-kit, PDGF and Abl receptor tyrosine kinases and has proven successful in the treatment of CML and GIST patients. Here, we investigated the potential role of STI571 in pancreatic cancer.

Results

The GI50 of STI571 as well as the effects of STI571 on growth factor actions in pancreatic cell lines were analyzed using the MTT assay. FACS analysis using Annexin and PI staining was performed to study cell cycle, apoptosis, and cell death. Western blot analysis was carried out to investigate MAP kinase and receptor tyrosine kinase phosphorylation. STI571 inhibited cell proliferation in pancreatic cancer cell lines with GI50 concentrations ranging from 17 to 31.5 microM. EGF, IGF-1, and FGF-2 but not PDGF exerted growth stimulatory effects in pancreatic cancer cell lines. STI571 only partly blocked these effects on cell growth, and did not abrogate growth factor-induced receptor and MAPK phosphorylation.

Conclusion

Our data demonstrate that STI571 inhibits pancreatic cancer cell growth with high GI50 concentrations through tyrosine-kinase receptor independent pathways. The clinical application of STI571 in pancreatic cancer is therefore rather doubtful.
Appendix
Available only for authorised users
Literature
1.
2.
Coppola D: Molecular prognostic markers in pancreatic cancer. Cancer Control. 2000, 7: 421-427.PubMed
3.
4.
5.
Heinemann V: Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials. Semin Oncol. 2002, 29: 9-16. 10.1053/sonc.2002.37372CrossRefPubMed
6.
van der Schelling GP, Jeekel J: Palliative chemotherapy and radiotherapy for pancreatic cancer: is It worthwhile?. World J Surg. 1999, 23: 950-953. 10.1007/s002689900605CrossRefPubMed
7.
Friess H, Buchler M, Kruger M, Beger HG: Treatment of duct carcinoma of the pancreas with the LH-RH analogue buserelin. Pancreas. 1992, 7: 516-521.CrossRefPubMed
8.
Friess H, Buchler M, Beglinger C, Weber A, Kunz J, Fritsch K, Dennler HJ, Beger HG: Low-dose octreotide treatment is not effective in patients with advanced pancreatic cancer. Pancreas. 1993, 8: 540-545.CrossRefPubMed
9.
Buchler M, Friess H, Schultheiss KH, Gebhardt C, Kubel R, Muhrer KH, Winkelmann M, Wagener T, Klapdor R, Kaul M, : A randomized controlled trial of adjuvant immunotherapy (murine monoclonal antibody 494/32) in resectable pancreatic cancer. Cancer. 1991, 68: 1507-1512.CrossRefPubMed
10.
Korc M: Role of growth factors in pancreatic cancer. Surg Oncol Clin N Am. 1998, 7: 25-41.PubMed
11.
Ozawa F, Friess H, Tempia-Caliera A, Kleeff J, Buchler MW: Growth factors and their receptors in pancreatic cancer. Teratog Carcinog Mutagen. 2001, 21: 27-44. 10.1002/1520-6866(2001)21:1<27::AID-TCM4>3.0.CO;2-9CrossRefPubMed
12.
Ebert M, Yokoyama M, Friess H, Kobrin MS, Buchler MW, Korc M: Induction of platelet-derived growth factor A and B chains and over-expression of their receptors in human pancreatic cancer. Int J Cancer. 1995, 62: 529-535.CrossRefPubMed
13.
Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996, 2: 561-566.CrossRefPubMed
14.
Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB, Gilliland DG, Druker BJ: CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood. 1997, 90: 4947-4952.PubMed
15.
McGary EC, Weber K, Mills L, Doucet M, Lewis V, Lev DC, Fidler IJ, Bar-Eli M: Inhibition of Platelet-derived Growth Factor-mediated Proliferation of Osteosarcoma Cells by the Novel Tyrosine Kinase Inhibitor STI571. Clin Cancer Res. 2002, 8: 3584-3591.PubMed
16.
Krystal GW, Honsawek S, Litz J, Buchdunger E: The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res. 2000, 6: 3319-3326.PubMed
17.
Esposito I, Kleeff J, Bischoff SC, Fischer L, Collecchi P, Iorio M, Bevilacqua G, Buchler MW, Friess H: The stem cell factor-c-kit system and mast cells in human pancreatic cancer. Lab Invest. 2002, 82: 1481-1492.CrossRefPubMed
18.
Wang WL, Healy ME, Sattler M, Verma S, Lin J, Maulik G, Stiles CD, Griffin JD, Johnson BE, Salgia R: Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene. 2000, 19: 3521-3528. 10.1038/sj.onc.1203698CrossRefPubMed
19.
Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001, 344: 1031-1037. 10.1056/NEJM200104053441401CrossRefPubMed
20.
Okuda K, Weisberg E, Gilliland DG, Griffin JD: ARG tyrosine kinase activity is inhibited by STI571. Blood. 2001, 97: 2440-2448. 10.1182/blood.V97.8.2440CrossRefPubMed
21.
Deininger MW, Goldman JM, Lydon N, Melo JV: The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood. 1997, 90: 3691-3698.PubMed
22.
Beran M, Cao X, Estrov Z, Jeha S, Jin G, O'Brien S, Talpaz M, Arlinghaus RB, Lydon NB, Kantarjian H: Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190, 000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin Cancer Res. 1998, 4: 1661-1672.PubMed
23.
Torrisani J, Buscail L: [Molecular pathways of pancreatic carcinogenesis]. Ann Pathol. 2002, 22: 349-355.PubMed
24.
Shi X, Friess H, Kleeff J, Ozawa F, Buchler MW: Pancreatic cancer: factors regulating tumor development, maintenance and metastasis. Pancreatology. 2001, 1: 517-524. 10.1159/000055854CrossRefPubMed
25.
Korc M, Chandrasekar B, Yamanaka Y, Friess H, Buchier M, Beger HG: Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Invest. 1992, 90: 1352-1360.PubMedCentralCrossRefPubMed
26.
Yamanaka Y, Friess H, Buchler M, Beger HG, Uchida E, Onda M, Kobrin MS, Korc M: Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage. Cancer Res. 1993, 53: 5289-5296.PubMed
27.
Kornmann M, Beger HG, Korc M: Role of fibroblast growth factors and their receptors in pancreatic cancer and chronic pancreatitis. Pancreas. 1998, 17: 169-175.CrossRefPubMed
28.
Kleeff J, Ishiwata T, Kumbasar A, Friess H, Buchler MW, Lander AD, Korc M: The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J Clin Invest. 1998, 102: 1662-1673.PubMedCentralCrossRefPubMed
29.
El-Hariry I, Pignatelli M, Lemoine NR: FGF-1 and FGF-2 regulate the expression of E-cadherin and catenins in pancreatic adenocarcinoma. Int J Cancer. 2001, 94: 652-661. 10.1002/ijc.1515CrossRefPubMed
30.
Bergmann U, Funatomi H, Yokoyama M, Beger HG, Korc M: Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res. 1995, 55: 2007-2011.PubMed
31.
Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ, Lydon NB: Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 1996, 56: 100-104.PubMed
32.
Zhang P, Gao WY, Turner S, Ducatman BS: Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro. Mol Cancer. 2003, 2: 1- 10.1186/1476-4598-2-1PubMedCentralCrossRefPubMed
33.
Sjoblom T, Shimizu A, O'Brien KP, Pietras K, Dal Cin P, Buchdunger E, Dumanski JP, Ostman A, Heldin CH: Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res. 2001, 61: 5778-5783.PubMed
34.
Attoub S, Rivat C, Rodrigues S, Van Bocxlaer S, Bedin M, Bruyneel E, Louvet C, Kornprobst M, Andre T, Mareel M, Mester J, Gespach C: The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy. Cancer Res. 2002, 62: 4879-4883.PubMed
35.
Boren J, Cascante M, Marin S, Comin-Anduix B, Centelles JJ, Lim S, Bassilian S, Ahmed S, Lee WN, Boros LG: Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells. J Biol Chem. 2001, 276: 37747-37753.PubMed
Metadata
Title
Effects of STI571 (gleevec) on pancreatic cancer cell growth
Authors
Junsheng Li
Jörg Kleeff
Junchao Guo
Lars Fischer
Nathalia Giese
Markus W Büchler
Helmut Friess
Publication date
01-12-2003
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2003
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-2-32

Other articles of this Issue 1/2003

Molecular Cancer 1/2003 Go to the issue

Editorial

Cancer cachexia

Retraction Note

Retraction Note: Association of Ataxia Telangiectasia Mutated (ATM) Gene Mutation/Deletion with Rhabdomyosarcoma – retraction

Review

Lipoxygenase and cyclooxygenase metabolism: new insights in treatment and chemoprevention of pancreatic cancer

Research

Interfering with TGFβ-induced Smad3 nuclear accumulation differentially affects TGFβ-dependent gene expression

Review

Apoptosis: Targets in Pancreatic Cancer

Review

The Biology of the Ets1 Proto-Oncogene
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits